Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06427668




Registration number
NCT06427668
Ethics application status
Date submitted
13/05/2024
Date registered
24/05/2024
Date last updated
13/08/2024

Titles & IDs
Public title
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
Scientific title
A Phase 2, Randomized, Placebo-controlled, Double-Blind Multicenter Study to Assess the Safety, Tolerability, and Pharmacodynamics (PD) in Adult Participants With Mild-to Moderate Alzheimer's Disease (AD) Administered SPG302
Secondary ID [1] 0 0
SPG302-ALZ-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SPG302
Treatment: Drugs - Placebo

Active comparator: Part A: Active SPG302 to be administered to adult participants with AD - Cohort 1: 12 participants with Alzheimer's Disease will be randomized in a 2:1 ratio to receive SPG302 or placebo. Study intervention will be 300 mg orally once daily for 28 days (cycle 1). All participants will receive open-label SPG302 for cycles 2-7. This arm may be expanded to cohort 2: 12 additional participants pending review of data, for additional dose exploration.

Placebo comparator: Part A: Placebo comparator to be administered to adult participants with AD - Cohort 1: 12 participants with Alzheimer's Disease will be randomized in a 2:1 ratio to receive SPG302 or placebo. Study intervention will be placebo capsule orally daily for 28 days (cycle 1). All participants will receive open-label SPG302 for cycles 2-7. This arm may be expanded to 12 additional participants as cohort 2 pending review of data, for additional dose exploration.

Experimental: Part B: Expansion Cohort - Dose to be used and size of dosing cohort to be determined by Data Safety and Monitoring Committee following completion of Part A.


Treatment: Drugs: SPG302
synthetic small molecule

Treatment: Drugs: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in Electroencephalogram (EEG) at resting state and at auditory evoked P300 from baseline to endpoint
Timepoint [1] 0 0
8 months
Primary outcome [2] 0 0
Change in Alzheimer's Disease Assessment Scale-Cog (ADAS-COG) total score from baseline to endpoint
Timepoint [2] 0 0
8 months
Primary outcome [3] 0 0
Change in Mini-Mental State Examination (MMSE) from baseline to endpoint
Timepoint [3] 0 0
8 months
Primary outcome [4] 0 0
C-SSRS (Columbia Suicide Severity Rating Scale)
Timepoint [4] 0 0
8 months
Primary outcome [5] 0 0
Change in Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS - CGIC) from baseline to endpoint
Timepoint [5] 0 0
8 months
Primary outcome [6] 0 0
Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale from baseline to endpoint
Timepoint [6] 0 0
8 months
Primary outcome [7] 0 0
Quality of Life in Alzheimer's Disease (QOL-AD) from baseline to endpoint
Timepoint [7] 0 0
8 months
Secondary outcome [1] 0 0
Safety and tolerability of SPG302
Timepoint [1] 0 0
8 months
Secondary outcome [2] 0 0
Plasma pharmacokinetics of SPG302 in participants with AD-Maximum Plasma Concentration (Cmax)
Timepoint [2] 0 0
8 months
Secondary outcome [3] 0 0
Change in biomarkers in participants with AD from baseline to endpoint.
Timepoint [3] 0 0
8 months

Eligibility
Key inclusion criteria
* Age 45-85
* Diagnosis of mild to moderate AD
* Clinical laboratory values within normal range or < 1.5 times ULN
* If receiving AD-specific treatment, have been on stable dose for = 3 months prior to first dose of study drug.
* Life expectancy of >2 years
* Able and willing to provide written informed consent
Minimum age
45 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Any physical or psychological condition that prohibits study completion
* Known cardiac disease
* Active or history of malignancy in the past 5 years
* Serious infection that will not be resolved by first day of study intervention.
* History of clinically significant CNS event or diagnosis in the past 5 years.
* Acute illness within 30 days of Day 1
* History of suicidal behavior or suicidal ideation
* History of chronic alcohol use or substance abuse in the last 5 years
* HIV, hepatitis B and/or hepatitis C positive
* Vaccines within 14 days
* Receipt of investigational products within 30 days
* Blood donation within 30 days
* Pregnant or breastfeeding

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
29/07/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2026
Actual
Sample size
Target
24
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA
Recruitment hospital [1] 0 0
St Vincent's Hospital - Sydney
Recruitment hospital [2] 0 0
Flinders Medical center - Adelaide
Recruitment postcode(s) [1] 0 0
2010 - Sydney
Recruitment postcode(s) [2] 0 0
5000 - Adelaide

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Spinogenix
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.
Trial website
https://clinicaltrials.gov/study/NCT06427668
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Lauren Priest, MBBS
Address 0 0
Flinders Medical Center, Adelaide, SA, Australia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
info Spinogenix
Address 0 0
Country 0 0
Phone 0 0
+61 2 8382 4977
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06427668